Short communicationIncorporation of synaptotagmin II to the axolemma of botulinum type-A poisoned mouse motor endings during enhanced quantal acetylcholine release
Section snippets
Acknowledgements
The work was supported in part by Association Française contre les Myopathies (AFM).
References (26)
- et al.
Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features
Neuroscience
(1990) - et al.
Mouse motor nerve terminal immunoreactivity to synaptotagmin II during sustained quantal transmitter release
Brain Res.
(1995) An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse
J. Neurol. Sci.
(1971)- et al.
Nerve terminal sprouting in botulinum type-A treated mouse Levator auris longus muscle
Neuromusc. Disord.
(1996) - et al.
α-Latrotoxin stimulate exocytosis by the interaction with a neuronal G-protein-coupled receptor
Neuron
(1997) - et al.
Effect of lanthanum ions on the amplitude distributions of miniature endplate potentials and on synaptic vesicles in frog neuromuscular junctions
Neuroscience
(1983) - et al.
α-Latrotoxin and related toxins
Pharmacol. Ther.
(1989) - et al.
From vesicle docking to endocytosis: intermediate reactions of exocytosis
Neuron
(1995) - et al.
Synaptotagmins: C2-domain proteins that regulate membrane traffic
Neuron
(1996) - et al.
Functional properties of multiple synaptotagmins in brain
Neuron
(1994)
Synaptotagmin I is a high affinity receptor for clathrin AP2: implications for membrane recycling
Cell
(1994)
Inhibition of neurotransmitter release by C2-domain peptides implicates synaptotagmin in exocytosis
Nature
(1993)
Effects of botulinum toxin on neuromuscular transmission in the rat
J. Physiol.
(1976)
Cited by (14)
Using mouse cranial muscles to investigate neuromuscular pathology in vivo
2010, Neuromuscular DisordersCitation Excerpt :Although not present in humans, these muscles have been utilised in a wide variety of studies into neurodegenerative disease and traumatic injury, where their phenotypic variation and accessibility have been capitalised upon. The superficial, subcutaneous location of LAL muscle had lead to its extensive use in studies into the effects of a range of ectopically applied drugs, growth factors and agonists on neuromuscular form and function (see, e.g. [11,13–17]). LAL has also been used to study the role of the translation elongation factor eEF1A2 in neurodegenerative disease [18].
Penelope's web: Using α-latrotoxin to untangle the mysteries of exocytosis
2009, Journal of NeurochemistryBotulinum Neurotoxin (BoNT) therapeutics: Time to think outside the BoNT?
2009, Botulinum Journal
Copyright © 1998 Elsevier Science B.V. All rights reserved.